Role Of CDKN2A A Cell Cycle Regulation in diagnosis of Oral Squamous Cell Carcinoma: A Review
Keywords:
Genes in Oral Cancer,CDKN2A in OSCC, OSCC Biomarkers, Saliva in OSCC, CDKN- cyclin dependent kinase, HNSCC- Head and Neck Squamous cell carcinoma, OSCC- Oral Squamous cell carcinomaAbstract
Oral squamous cell carcinoma (OSCC) represents a significant global health burden, marked by high mortality and poor prognosis. It is most commonly observed in individuals who consume tobacco, particularly long-term users. The disease arises from a series of cellular and molecular changes, including alterations in gene expression that drive cancer development. Understanding and potentially reversing these genetic and epigenetic changes may aid in disease prevention and treatment.
Among the key molecular aberrations involved in OSCC pathogenesis are alterations in the CDKN2A gene. Located on chromosome 9p21, CDKN2A encodes two critical tumor suppressor proteins—p16^INK4a^ and p14^ARF^—which regulate the cell cycle and apoptosis, respectively. Loss of function in CDKN2A disrupts these regulatory processes, thereby promoting cancer development.
This review explores the molecular biology of CDKN2A, its alterations in OSCC, the associated signaling pathways, and potential therapeutic implications. Epigenetic and genetic regulation of CDKN2A may offer promising strategies for cancer prevention and therapy. Ongoing research into this gene and its related pathways holds the potential to deliver transformative insights, ultimately improving prognostic accuracy and treatment outcomes for OSCC patients
Downloads
References
T. Hunter, J. Pines, Cyclins and cancer. II: cyclin D and CDK inhibitors come of age, Cell 79 (1994) 573–582
Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/ INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630.
Ohta S, Uemura H, Matsui Y, et al. Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:81.
Chen PL, Scully P, Shew JY, et al. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989;58:1193.
Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995;375:503.
Mihara K, Cao XR, Yen A, et al. Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 1989;246:1300.
Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488.
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999 CA Cancer J Clin. 1999;49:8–31
Sunny L, Yeole BB, Hakama M, Shiri R, Sastry PS, Mathews S, et al Oral cancers in Mumbai, India: A fifteen years perspective with respect to incidence trend and cumulative risk Asian Pac J Cancer Prev. 2004;5:294–300
Daftary DK, Murti PR, Bhonsle RB, et alJohnson NW Risk factors and risk markers for oral cancer in high incidence areas of the world Oral Cancer. 1991;Vol 2 Cambridge Cambridge University Press:29–63
Mehrotra R, Yadav S. Oral squamous cell carcinoma: etiology, pathogenesis and prognostic value of genomic alterations. Indian journal of cancer. 2006 Apr 1;43(2):60-6.
Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. Molecular medicine. 1997 Jan;3:5-20.
Cairns P, Mao L, Merlo A, et al. (1994) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415–417.
Fountain JW, Karayiorgou M, Ernstoff MS, et al. (1992) Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl. Acad. Sci. U.S.A. 89: 10557–10561.
Kamb A, Gruis NA, Weaver-Feldhaus J, et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436–440.
Rayess H, Wang MB, Srivatsan ES (April 2012). "Cellular senescence and tumor suppressor gene p16". International Journal of Cancer. 130 (8): 1715–25. doi:10.1002/ijc.27316. PMC 3288293. PMID 22025288.
^ Li Y, Nichols MA, Shay JW, Xiong Y (December 1994). "Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb". Cancer Research. 54 (23): 6078–82. PMID 7954450.
Robaina MC, Faccion RS, Arruda VO, de Rezende LM, Vasconcelos GM, Apa AG, Bacchi CE, Klumb CE (February 2015). "Quantitative analysis of CDKN2A methylation, mRNA, and p16(INK4a) protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications". Leukemia Research. 39 (2): 248–56. doi:10.1016/j.leukres.2014.11.023. PMID 25542698.
^ El-Naggar AK, Lai S, Clayman G, Lee JK, Luna MA, Goepfert H, Batsakis JG (December 1997). "Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma". The American Journal of Pathology. 151 (6): 1767–74. PMC 1858347. PMID 9403727.
Asokan GS, Jeelani S, Gnanasundaram N (October 2014). "Promoter hypermethylation profile of tumour suppressor genes in oral leukoplakia and oral squamous cell carcinoma". Journal of Clinical and Diagnostic Research. 8 (10): ZC09-12. doi:10.7860/JCDR/2014/9251.4949. PMC 4253256. PMID 25478438
Fostira F, Koutsodontis G, Vagia E, Economopoulou P, Kotsantis I, Sasaki C et al. Predisposing germline mutations in young patients with squamous cell cancer of the oral cavity JCO Precis Oncol 2018 2 1 -8
Oldenburg RA, de Vos tot Nederveen Capp Yarbrough WG, Aprelikova O, Pei H, Olshan AF, Liu ET Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele J Natl Cancer Inst 1996 88 20 1489 -1491 el WH, van Puijenbroek M, van den Ouweland A, Bakker E, Griffioen G et al. Extending the p16-Leiden tumour spectrum by respiratory tract tumours J Med Genet 2004 41 3 e31
Schneider-Stock R, Giers A, Motsch C, Boltze C, Evert M, Freigang B et al. Hereditary p16-Leiden mutation in a patient with multiple head and neck tumors Am J Hum Genet 2003 72 1 216 -218
Vinarsky V, Fine RL, Assaad A, Qian Y, Chabot JA, Su GH et al. Head and neck squamous cell carcinoma in FAMMM syndrome Head Neck 2009 31 11 1524 -1527
Yu KK, Zanation AM, Moss JR, Yarbrough WG Familial head and neck cancer: molecular analysis of a new clinical entity Laryngoscope 2002 112 9 1587 -1593
Negara I, Tomuleasa C, Buruiana S, Efremov DG. Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome. Cancers. 2024 Jun 7;16(12):2170.
Deneka AY, Baca Y, Serebriiskii IG, Nicolas E, Parker MI, Nguyen TT, Xiu J, Korn WM, Demeure MJ, Wise-Draper T, Sukari A. Association of T P53 and CDKN2A mutation profile with tumor mutation burden in head and neck cancer. Clinical Cancer Research. 2022 May 2;28(9):1925-37.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
